Posted by Michael Wonder on 06 Oct 2021
NICE terminates another appraisal for a Roche medicine
6 October 2021 - The sixth termination of the appraisal of a Roche medicine.
NICE is unable to make a recommendation on the use of baloxavir marboxil (Xofluza) for the treatment of people aged 12 and over with acute uncomplicated influenza. This is because Roche did not provide an evidence submission.
